Market closedNon-fractional
Celularity/CELU
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Celularity
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases.
Ticker
CELU
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Florham Park, United States
Employees
225
Website
www.celularity.com
Celularity Metrics
BasicAdvanced
$65M
Market cap
-
P/E ratio
-$11.00
EPS
0.24
Beta
-
Dividend rate
Price and volume
Market cap
$65M
Beta
0.24
Financial strength
Current ratio
0.195
Quick ratio
0.052
Long term debt to equity
86.204
Total debt to equity
201.931
Interest coverage (TTM)
-41.40%
Management effectiveness
Return on assets (TTM)
-20.48%
Return on equity (TTM)
-186.56%
Valuation
Price to revenue (TTM)
3.371
Price to book
1.9
Price to tangible book (TTM)
5.05
Price to free cash flow (TTM)
-0.731
Growth
Revenue change (TTM)
-20.93%
Earnings per share change (TTM)
934.65%
3-year revenue growth (CAGR)
-2.97%
3-year earnings per share growth (CAGR)
-54.71%
Celularity Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$3.7M
27.59%
Net income
-$94M
95.82%
Profit margin
-2,535.13%
53.48%
Celularity Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Actual
$0.02
-$0.04
-$0.03
-$0.05
Expected
-
-
-
-
Surprise
-
-
-
-
Celularity News
AllArticlesVideos
Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewsWire·2 months ago
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
GlobeNewsWire·2 months ago
Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Celularity stock?
Celularity (CELU) has a market cap of $65M as of July 27, 2024.
What is the P/E ratio for Celularity stock?
The price to earnings (P/E) ratio for Celularity (CELU) stock is 0 as of July 27, 2024.
Does Celularity stock pay dividends?
No, Celularity (CELU) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Celularity dividend payment date?
Celularity (CELU) stock does not pay dividends to its shareholders.
What is the beta indicator for Celularity?
Celularity (CELU) has a beta rating of 0.24. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Celularity stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.